Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Elsevier Science full text link Elsevier Science Free PMC article
Full text links

Actions

Review
.2014 May 25;389(1-2):71-83.
doi: 10.1016/j.mce.2014.02.002. Epub 2014 Feb 12.

Estrogen biology: new insights into GPER function and clinical opportunities

Affiliations
Review

Estrogen biology: new insights into GPER function and clinical opportunities

Eric R Prossnitz et al. Mol Cell Endocrinol..

Abstract

Estrogens play an important role in the regulation of normal physiology, aging and many disease states. Although the nuclear estrogen receptors have classically been described to function as ligand-activated transcription factors mediating genomic effects in hormonally regulated tissues, more recent studies reveal that estrogens also mediate rapid signaling events traditionally associated with G protein-coupled receptors. The G protein-coupled estrogen receptor GPER (formerly GPR30) has now become recognized as a major mediator of estrogen's rapid cellular effects throughout the body. With the discovery of selective synthetic ligands for GPER, both agonists and antagonists, as well as the use of GPER knockout mice, significant advances have been made in our understanding of GPER function at the cellular, tissue and organismal levels. In many instances, the protective/beneficial effects of estrogen are mimicked by selective GPER agonism and are absent or reduced in GPER knockout mice, suggesting an essential or at least parallel role for GPER in the actions of estrogen. In this review, we will discuss recent advances and our current understanding of the role of GPER and the activity of clinically used drugs, such as SERMs and SERDs, in physiology and disease. We will also highlight novel opportunities for clinical development towards GPER-targeted therapeutics, for molecular imaging, as well as for theranostic approaches and personalized medicine.

Keywords: 17β-Estradiol; Cardiac; Cardiovascular; GPR30; Immune; SERM.

Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Ligands of GPER and ERs. Agonists (green arrows), partial agonists (SERMS, orange arrow) and antagonists (red arrows) of GPER and the classical estrogen receptors ER and ER. SERMS and SERDs that f. SERMS and SERDs that function as ER antagonists in many tissues act as agonists of GPER. GPER-selective ligands (G-1, G15 and G36) are highly selective for GPER over ERs. Modified from (Meyer et al., 2011b), with permission of Elsevier Publishers.
Figure 2
Figure 2
Signaling pathways initiated by GPER and ERs. Endogenous estrogens, including 17 -estradiol (E2), represent nonselective activators of the three known ERs, ER, ER and GPER. Estrogen activates nuclear ERs, inducing dimerization of the receptors and binding of receptor dimers to target gene promoters. Alternatively, activated ERs modulate the function of other classes of transcription factors (TFs) through protein-protein interactions. Subpopulations of ERs at the plasma membrane following activation by estrogen interact with adaptor proteins (adaptor) and signaling molecules such asc-src, which mediates rapid signaling via PI3K/Akt and MAPK pathways. GPER, which is predominantly localized intracellularly, can be activated by estrogen, or selective GPER agonists (such as G-1), but also by selective estrogen receptor downregulators (such as fulvestrant), or selective estrogen receptor modulators (such as tamoxifen and raloxifene). GPER activation stimulates cAMP production, calcium mobilization andc-src, which activates MMPs. These MMPs cleave pro-HB-EGF, releasing free HB-EGF that transactivates EGFR, which in turn activates MAPK and PI3K/Akt pathways that can induce additional rapid (nongenomic) effects (X), or genomic effects regulating gene transcription. Estrogen-mediated transcriptional regulation may involve phosphorylation (P) of ER or other TFs that may directly interact with ER, or bind independently of ER within the promoters of target genes. Abbreviations: E2, 17 - estradiol; EGFR, epidermal growth factor receptor; ER, estrogen receptor; GPER, G-protein-coupled ER; MMP, matrix metalloproteinase; pro-HB-EGF, pro-heparin-binding epidermal growth factor; TF, transcription factor. Figure reproduced from (Prossnitz and Barton, 2011).
Figure 3
Figure 3
Current experimental and clinical evidence implicates a physiological role (shown in black) for GPER in neuroendocrine and cerebral functions, immunity and immune cell function, metabolic and endocrine regulation, vascular, myocardial, and kidney function, as well as development and reproductive functions. In addition, data obtained in experimental models of disease and/or tissue from patients with disease suggest roles for GPER in pathological conditions (shown in red), such as diabetes mellitus, arterial hypertension, proteinuric renal disease, osteoporosis, arthritis, immune diseases, such as multiple sclerosis, and cancer. Targeting GPER activity with highly selective ligands in humans may represent a novel approach for the treatment of these conditions, for molecular imaging, as well as for theranostic approaches and personalized medicine. Figure reproduced from (Prossnitz and Barton, 2011).
See this image and copyright information in PMC

References

    1. Abdelhamid R, Luo J, Vandevrede L, Kundu I, Michalsen B, Litosh VA, Schiefer IT, Gherezghiher T, Yao P, Qin Z, Thatcher GR. Benzothiophene selective estrogen receptor modulators provide neuroprotection by a novel GPR30-dependent mechanism. ACS Chem. Neurosci. 2011;2:256–268. - PMC - PubMed
    1. Albanito L, Lappano R, Madeo A, Chimento A, Prossnitz ER, Cappello AR, Dolce V, Abonante S, Pezzi V, Maggiolini M. G-protein-coupled receptor 30 and estrogen receptor-alpha are involved in the proliferative effects induced by atrazine in ovarian cancer cells. Environ. Health Perspect. 2008;116:1648–1655. - PMC - PubMed
    1. Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, Oprea TI, Prossnitz ER, Musti AM, Ando S, Maggiolini M. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res. 2007;67:1859–1866. - PubMed
    1. Alexander SP, Mathie A, Peters JA. Guide to Receptors and Channels (GRAC), 5th edition. Br. J. Pharmacol. 2011;164(Suppl 1):S1–324. - PMC - PubMed
    1. Anbalagan M, Huderson B, Murphy L, Rowan BG. Post-translational modifications of nuclear receptors and human disease. Nucl Recept Signal. 2012;10:e001. - PMC - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full text links
Elsevier Science full text link Elsevier Science Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp